Age-dependent improvement in median and long-term survival in unselected population-based nordic registries of patients with synchronous metastatic colorectal cancer

Annals of Oncology

Volumn 24, Issue 9, 2013, Pages 2354-2360

  Sorbye, H ^a   Cvancarova, M ^b   Qvortrup, C ^c   Pfeiffer, P ^c   Glimelius, B ^d,e  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d UPPSALA UNIVERSITY   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

5 year survival; Cancer registries; Elderly; Median survival; Metastatic colorectal cancer

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; DATA ANALYSIS; DENMARK; ETHNIC DIFFERENCE; ETHNIC GROUP; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MEDIAN SURVIVAL; METASTATIC COLORECTAL CANCER; NORWAY; NORWEGIAN; POPULATION RESEARCH; PRIORITY JOURNAL; SURVIVAL RATE; SWEDEN; TREATMENT OUTCOME;

5-YEAR SURVIVAL; CANCER REGISTRIES; ELDERLY; MEDIAN SURVIVAL; METASTATIC COLORECTAL CANCER;

ADENOCARCINOMA; AGE FACTORS; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DENMARK; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NORWAY; REGISTRIES; SURVIVAL; SWEDEN; TREATMENT OUTCOME;

EID: 84883312133     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt197     Document Type: Article

References (21)

1. Tveit KM, Guren T, Glimelius B et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin and oxaliplatin (Nordic FLOX) versus FLOX alone in firstline treatment of metastatic colorectal cancer: The NORDIC-VII study. J Clin Oncol 2012; 30: 1755-1762.
2. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27: 3677-3683.
3. Meulenbeld HJ, van Steenbergen LN, Janssen-Heijnen ML, et al. Significant improvement in survival of patients presenting with metastatic colon cancer in the south of the Netherlands from 1990 to 2004. Ann Oncol 2008; 19: 1600-1604.
4. Lemmens VE, de Haan N, Rutten HJ, et al. Improvements in populationbased survival of patients presenting with metastatic rectal cancer in the south of the Netherlands, 1992-2008. Clin Exp Metastasis 2011; 28: 283-290.
5. van Steenbergen LN, Elferink MAG, Krijnen P, et al. Improved survival of colon cancer due to improved treatment and detection: a nationwide population-based study in the Netherlands 1989-2006. Ann Oncol 2010; 21: 2206-2212.
6. Sorbye H, Pfeiffer P, Cavalli-Bjorkman N, et al. Clinical trial enrolment, patient characteristics, and survival differences in prospective registered metastatic colorectal cancer patients. Cancer 2009; 15: 4679-4687.
7. Khattak MA, Townsend AR, Beeke C, et al. Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer. Eur J Cancer 2012; 48: 1293-1298.
8. Sorbye H, Köhne CH, Sargent DJ, et al. Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification. Ann Oncol 2007; 10: 1666-1672.
9. Arkenau HT, Nordman I, Dobbins T, et al. Reporting time-to-event endpoints and response rates in 4 decades of randomized trials in advanced colorectal cancer. Cancer 2011; 117: 832-840.
10. Larsen IK, Smaastuen M, Johannesen TB, et al. Data quality and the Cancer Registry of Norway. Eur J Cancer 2009; 45: 1218-1231.
11. Khani MH, Pahlman L, Smedh K. Treatment strategies for patients with stage IV rectal cancer. Eur J Cancer 2012; 48: 1616-1623.
12. Elferink MAG, van Steenbergen LN, Krijnen P, et al. Marked improvement in survival of patients with rectal cancer in the Netherlands following changes in therapy, 1989-2006. Eur J Cancer 2010; 46: 1421-1429.
13. Adam R, Haller DG, Poston G, et al. Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer. Ann Oncol 2010; 8: 1579-1584.
14. McKibbin T, Frei CR, Greene RE, et al. Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting. Oncologist 2008; 13: 876-885.
15. Shayne M, Culakova E, Poniewierski MS, et al. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer 2007; 110: 1611-1620.
16. Christensen K, Doblhammer G, Rau R, et al. Ageing populations: the challenges ahead. Lancet 2009; 374: 1196-1208.
17. Seymour MT, Thompson LC, Wasan HS, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (FOCUS2): an open-label, randomised factorial trial. Lancet 2011; 377: 1749-1759.
18. Hedden L, Kennecke H, Villa D, et al. Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada. Eur J Cancer 2012; 48: 1969-1976.
19. Mol L, Koopman M, vanGils CW, et al. Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands. Acta Oncol 2013; 52: 950-955.
20. Morris EJ, Forman D, Thomas JD, et al. Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg 2010; 97: 1110-1118.
21. Mekenkamp LJ, Koopman M, Teerenstra S, et al. Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. Br J Cancer 2010; 103: 159-164.